The director of the National Institute on Drug Abuse, Dr. Nora Volkow, has just published an essay in the Huffington Post entitled “Researching Marijuana for Therapeutic Purposes: The Potential Promise of Cannabidiol (CBD).” A pro-cannabis friend forwarded the link, calling it “a powerful statement.”
Given NIDA’s history and prohibitionist mission, Volkow’s piece can be seen as a step in the right direction. She calls for “addressing barriers that slow clinical research” —a reference to CBD’s absurd status as a Schedule I substance. But that shy, sly allusion is hardly a powerful statement. In fact, “potential promise” — the redundant phrase in the title of Volkow’s CBD essay— reveals an almost laughable level of timidity. And it’s misleading to the point of dishonesty.
Yes, there are many potential uses of CBD for researchers to explore. But the ability of cannabidiol to alleviate symptoms in a wide range of illnesses has been proven —determined, established, QED, confirmed, made evident— in many studies involving animals, several trials with human patients, and thousands of cases monitored by physicians in California, Colorado, and other states where medical use is legal.
To repeat: CBD provides medical benefit. That is a fact, not a “potential promise.”
[ux_featured_products products=”” columns=”4″ title=”Check our Featured products!”] Watch Full Movie Online Streaming Online and Download